报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2024年4月18日， 怡和嘉业 发布了2024年年报。 # 财报数据 # 关于 怡和嘉业 北京怡和嘉业医疗科技股份有限公司成立于 2001 年，位于北京市海淀区，是一家 专注于呼吸健康领域医疗 设备与耗材产品研发、生产、销售及相关服务 的高新技术企业。公司主要为以阻塞型睡眠呼吸暂停低通气综 合征（OSA）为主的睡眠呼吸暂停低通气综合征（SAHS）患者，以及以慢性阻塞性肺疾病（COPD）为主的 呼吸功能不全（Respiratory Insufficiency）患者提供全周期（从诊断、治疗到慢病管理）、多场景（从医疗 机构到家庭）的治疗服务整体解决方案。 持。 技术优势 ：BMC 呼吸机国产化率在 90% 以上，避免了因关键器件依赖进口可能导致的生产中断问 题；研发的智能无创呼吸机系列采用先进的智能传感控制技术和优异的生产工艺。 市场与合作 市场覆盖 ：产品销售覆盖全球 100 多个国家和地区，取得 NMPA、FDA、CE 等认证。是市场上少有 的家用无创呼吸机产品进入美国、德国、意大利、土耳 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown a recovery in revenue growth quarter by quarter, with a significant increase in the proportion of consumables in its business [2] - The company is increasing its R&D investment and optimizing its supply chain, which is expected to enhance profitability [2] - Revenue forecasts for 2025-2027 indicate a positive growth trajectory, with expected revenues of 10.58 billion, 13.14 billion, and 16.21 billion respectively, and corresponding net profits of 2.06 billion, 2.69 billion, and 3.43 billion [2] Summary by Relevant Sections Financial Performance - In 2024, the company achieved total revenue of 843 million (down 24.85% YoY) and a net profit of 155 million (down 47.74% YoY) [3] - The revenue for Q4 2024 was 241 million (up 36.29% YoY), with a net profit of 30 million (up 12.65% YoY) [3] - The company’s gross margin improved to 48.3% in 2024, with a projected gross margin of 49.3% in 2025 [3] Revenue Breakdown - The company’s consumables revenue reached 284 million in 2024, representing a 46.22% increase YoY, and accounted for 33.72% of total revenue [2] - The revenue from home respiratory therapy products was 527 million (down 38.15% YoY), primarily due to inventory destocking in overseas markets [2] Profitability Metrics - The sales expense ratio increased to 13.36% (up 4.06 percentage points YoY), while the management expense ratio rose to 7.29% (up 3.70 percentage points YoY) [2] - The net profit margin for 2024 was 18.80% (down 7.91 percentage points YoY) [2] Future Projections - Expected revenue growth rates for 2025, 2026, and 2027 are 25.4%, 24.2%, and 23.4% respectively [2] - The projected net profit growth rates for the same period are 32.4%, 30.6%, and 27.7% respectively [2]

2025年4月18日，怡和嘉业(301367.SZ)发布2024年年度报告。截至2025年4月17日，共有171个机构投资 者披露持有怡和嘉业A股股份，合计持股量达4080.92万股，占怡和嘉业总股本的45.55%。其中，前十 大机构投资者包括珠海合晅投资中心(有限合伙)、北京润脉投资发展中心(有限合伙)、上海盛旻创业投 资合伙企业(有限合伙)、能金有限公司、中信证券股份有限公司-社保基金17052组合、中信证券股份有 限公司-社保基金17052组合、全国社保基金四一八组合、广州市金垣创业投资合伙企业(有限合伙)、瑞 众人寿保险有限责任公司-自有资金、东方精选混合，前十大机构投资者合计持股比例达38.51%。相较 于上一季度，前十大机构持股比例合计下跌了1.45个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计4个，包括招商信用增强债券A、东方精选混 合、银华永祥灵活配置混合、金信价值精选混合A，持股增加占比小幅上涨。本期较上一季度持股减少 的公募基金共计6个，主要包括国投瑞银医疗保健混合A、浙商智选新兴产业混合A、天弘鑫悦成长A、 国投瑞银创新医疗混合A、浙商聚潮新思维混合A等，持股减少占比达0. ...

重要公告： 华鲁恒升：拟2亿元—3亿元回购股份用于注销 亚振家居：控股股东筹划控制权变更事项股票18日起停牌 中国联通：一季度净利润同比增长6.5% 同飞股份：一季度净利润同比增长1104.89% 长盈精密：2024年净利润同比增长800.24% 拟10派1.3元 沪市重要公告： 华鲁恒升：拟2亿元—3亿元回购股份用于注销 亚振家居（603389）公告，因公司控股股东上海亚振投资有限公司正在筹划重大事项，该事项可能导致 公司控制权发生变更，经公司申请，公司股票将于2025年4月18日（星期五）开市起停牌，停牌时间不 超过2天。 圣泉集团：一季度净利润同比增长50.46% 圣泉集团（605589）公告，第一季度实现营业收入24.59亿元，同比增长15.14%；净利润2.07亿元，同 比增长50.46%；基本每股收益0.25元。 中国联通：一季度净利润同比增长6.5% 中国联通（600050）公告，公司2025年第一季度实现营业收入1033.5亿元，同比增长3.9%；归属于母公 司净利润26.1亿元，同比增长6.5%；基本每股收益0.083元。 华鲁恒升（600426）公告，公司拟2亿元—3亿元回购股份用于注销并 ...

Group 1 - Sanan Optoelectronics received a loan commitment letter from China Industrial Bank for a repurchase loan of 1 billion yuan, valid for three years, to support stock buybacks [2] - Changying Precision reported a 23.40% increase in revenue to 16.934 billion yuan and an 800.24% increase in net profit to 772 million yuan for 2024, driven by humanoid robot projects [2] - Zhuhai Group's Q1 net profit increased by 74.07% to 277 million yuan, attributed to gains from precious metals [2] Group 2 - Qianyuan Power expects a Q1 net profit increase of 330%-365%, driven by a 62.70% increase in water inflow and a 59.40% rise in power generation [3] - Guofang Group's stock has experienced significant volatility, with a current P/E ratio of 110.1, indicating potential irrational speculation [3] - Fangyuan Co. decided to terminate a 3 billion yuan lithium carbonate production project due to market conditions and strategic changes, having already invested 97 million yuan [4] Group 3 - Baosteel plans to acquire a 49% stake in Maanshan Steel for a total consideration of 9 billion yuan, consisting of 5.139 billion yuan for equity purchase and 3.861 billion yuan for capital increase [5]

怡和嘉业（301367）公告，2024年营业收入8.43亿元，同比下降24.85%。归属于上市公司股东的净利润 1.55亿元，同比下降47.74%。基本每股收益1.74元/股。公司拟向全体股东每10股派发现金红利4元(含 税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

Core Viewpoint - The Chinese medical device industry is focusing on technological breakthroughs and practical applications to navigate the complex global political and economic landscape, as discussed at the 91st China International Medical Equipment Fair (CMEF) [2] Group 1: Industry Trends and Innovations - Companies are leveraging AI technology to enhance product competitiveness and are seizing opportunities from domestic consumption promotion initiatives [3] - The exhibition showcased a wide range of digital products and AI innovations, indicating a shift towards intelligent technology and ecosystem collaboration [3] - The introduction of national policies like "national subsidies" and "trade-in for new consumption" has significantly boosted domestic sales of medical devices [4][8] Group 2: Company Performance and Market Position - The brand "瑞迈特" under the company has achieved a global market share of 12.4% in 2023, ranking second globally, and holds a 30.6% share in the domestic market, leading the sector [6] - The company's overseas revenue reached 219 million yuan, accounting for 57.20% of total revenue, while domestic revenue was 164 million yuan, making up 42.80% [6] - The company perceives the domestic market as having stronger certainty compared to overseas markets, but it remains committed to global expansion [6][7] Group 3: Consumer Behavior and Policy Impact - The introduction of subsidies has led to increased sales, with significant price reductions for products like the 瑞迈特 E5 B20A Plus respiratory machine due to government and platform subsidies [8] - The recent government initiative to support consumption with a special bond of 300 billion yuan aims to stimulate short-term consumption and encourage technological upgrades in products [8] Group 4: Future Development and Strategic Focus - The company is focusing on enhancing its product offerings through AI and digital technologies, aiming to provide comprehensive health management rather than just treating illnesses [9][10] - The company plans to strengthen its clinical channel to build brand image and engage with healthcare professionals, while also investing in algorithm updates and new material research [10]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][50]. Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16]. - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points, ranking 22nd among 31 sub-industries [19][24]. Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective and human-relevant methods, which could enhance drug safety and lower costs [14][15]. - The shift is anticipated to accelerate drug development timelines and improve success rates, particularly benefiting companies involved in AI drug development such as Jingtai Holdings and Chengdu Xian Dao [6][17]. Subsector Performance - The blood products sector saw the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline at 16.04% [7][23]. - The medical device sector decreased by 2.62%, and the traditional Chinese medicine sector fell by 3.35% [7][23]. Recommended and Benefiting Stocks - Recommended stocks include Weidian Physiotherapy, Maipu Medical, and Yingke Medical [8][31]. - Benefiting stocks from the FDA policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17]. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from the "old-for-new" policy and increased procurement activities in Q2 2025, with a current P/E ratio of 32.15, indicating potential for valuation growth [27][29]. - **Medical Consumables**: This sector is under pressure due to US-China tariff impacts, but certain segments are expected to perform well due to high growth potential and improved conditions [30]. - **IVD Sector**: The IVD sector is projected to recover as AI technologies enhance diagnostic capabilities, despite current pressures from procurement policies [33]. - **Blood Products**: The sector is expected to benefit from rising domestic production and increased focus on local sourcing due to tariff impacts [35]. - **Retail Pharmacy**: The offline pharmacy sector is seeing a recovery in customer traffic and profitability, with major players expected to leverage AI for operational efficiency [37][38].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16] - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points [19][24] - The blood products sector showed the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline, dropping by 16.04% [7][19][23] Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective human-relevant methods in drug development, which could enhance drug safety and lower costs [14][15] - The pharmaceutical sector's performance this week was marked by significant declines across various sub-sectors, with blood products being the only one to gain [19][23] Sub-sector Performance - Blood products increased by 4.06%, while medical outsourcing fell by 16.04%, indicating a significant divergence in performance among sub-sectors [7][19][23] - The medical device sector's P/E ratio is currently at 32.15, suggesting potential for valuation increases [27] - The IVD sector is also seen as having room for valuation growth, with a current P/E of 21.89 [33] Recommended and Benefiting Stocks - Recommended stocks include Microelectrophysiology, Maipu Medical, and Yingke Medical, among others [8][31][38] - Benefiting stocks from the FDA's policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17] Market Trends - The report highlights a structural investment opportunity in the pharmaceutical sector, driven by policy support and AI-enabled R&D [26] - The report notes that the medical device sector is expected to benefit from upcoming procurement policies and a low base effect in Q2 2025 [27][29]

Group 1 - The U.S. government has implemented a 10% "minimum benchmark tariff" on trade partners, with certain exemptions for pharmaceuticals and other products [1][2] - The pharmaceutical sector has reacted negatively in the market, with significant declines in various related sectors, including medical services and biopharmaceuticals, with drops ranging from 9.55% to 14.69% [1] - The exemption of pharmaceuticals from the tariff is due to the high reliance of the U.S. on imported active pharmaceutical ingredients (APIs), with 80% of APIs sourced from abroad [2][3] Group 2 - Local pharmaceutical companies have reported minimal impact from the tariff changes, as the tariffs do not apply to innovative drug licensing and trade [5][6] - Companies like Mindray Medical and others have proactively prepared for potential tariff impacts by adjusting their supply chains and inventory strategies [6][5] - The focus on high-quality innovation is emphasized as a key strategy for the Chinese pharmaceutical industry to navigate the challenges posed by tariffs and global competition [8][7] Group 3 - The number of innovative drugs developed by Chinese companies is rapidly increasing, with projections indicating that by the end of 2024, there will be 3,575 active innovative drugs, surpassing the U.S. [7] - Chinese pharmaceutical companies are actively expanding into international markets, with significant license-out transactions and collaborations with multinational corporations [7][8] - The "NewCo" model is emerging as a viable path for Chinese biopharmaceutical companies to innovate and expand internationally, despite geopolitical challenges [8]